KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 140 patients (estimated)
- Sponsors
- Keros Therapeutics, Inc.
- Tags
- Growth Factor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1646
- NCT Identifier
- NCT04419649
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.